Drugs / CD123-CART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04318678 | Jul 2020 → Jul 2029 expected | CD4+/CD56+ hematodermic neoplasm, T-cell acute lymphoblastic leukemia, acute myeloid leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03473457 | Apr 2018 → Dec 2020 | acute myeloid leukemia | Zhujiang Hospital | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD123-CAR T | “one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)” NCT03473457 ↗ |
| Modality | Cell therapy | “The CD123-CAR T-cell therapy is a new treatment” NCT04318678 ↗ |
| Route | Intravenous | “one intravenous infusion of escalating doses of autologous, CD123-CAR T cells” NCT04318678 ↗ |